Antidiabetic bicyclic compounds
View Patent ↗Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
1. A compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein Ar is selected from the group consisting of phenyl, naphthyl, a 5-6 membered monocyclic heteroaromatic group having 1-3 heteroatoms independently selected from N, O, and S, and a benzoheteroaromatic group comprising a phenyl ring fused to a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S,
wherein Ar is optionally substituted with 1-2 aromatic groups independently selected from phenyl, phenoxy, benzyl, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S and is optionally substituted with 1-5 substituents independently selected from halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-6 alkyl, —C 3-6 cycloalkyl, —OC 1-6 alkyl, —SC 1-6 alkyl, —C(═O)C 1-6 alkyl, —OC(═O)C 1-6 alkyl, —C(═O)OC 1-6 alkyl, —S(O) 2 C 1-6 alkyl, —NR 13 R 14 , —C(═O)N(R 13 )(R 14 ), —S(O) 2 NR 13 R 14 , and —OC 3-6 cycloalkyl, wherein (a) C 1-6 alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC 1-4 alkyl optionally substituted with 1-5 halogens, (b) —C 3-6 cycloalkyl in all instances is optionally substituted with 1-2 substituents independently selected from halogen and CH 3 , and (c) the aromatic substituent groups phenyl, phenoxy, benzyl, and the 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S are optionally substituted with 1-5 groups independently selected from halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-6 alkyl, —OC 1-6 alkyl, —SC 1-6 alkyl, —C(═O)C 1-6 alkyl, —OC(═O)C 1-6 alkyl, —C(═O)OC 1-6 alkyl, —S(O) 2 C 1-6 alkyl, NR 13 R 14 , —C(═O)N(R 13 )(R 14 ), —S(O) 2 NR 13 R 14 , and —O(CH 2 )q(4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N), wherein C 1-6 alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC 1-4 alkyl optionally substituted with 1-5 halogens, and the 4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N is optionally substituted with 1-2 groups independently selected from halogen, CH 3 , and CF 3 ;
X is selected from the group consisting of —O—, —S—, —S(O)—, —S(O) 2 —, —NR 5 —, —OCR 10 R 11 —, —SCR 10 R 11 —, —NR 5 CR 10 R 11 —, —CR 10 R 11 O—, —CR 10 R 11 S—, —CR 10 R 11 NR 5 —, and —CR 6 R 7 CR 8 R 9 O—;
Y is selected from the group consisting of —O—, —S—, —S(O)—, —S(O) 2 —, —NR 5 —, —C(═O)—, —CR 6 R 7 —, —OCR 6 R 7 —, —SCR 6 R 7 —, and —CR 6 R 7 CR 8 R 9 —;
Z is selected from the group consisting of —C(═O)OR 12 , —C(═O)NR 13 R 14 , and 5-tetrazolyl;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of H, halogen, C 1-3 alkyl, and —OC 1-3 alkyl, wherein C 1-3 alkyl, and —OC 1-3 alkyl are each optionally substituted with 1-3 halogens;
R 4 is selected from the group consisting of halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-6 alkyl, —OC 1-6 alkyl, —SC 1-6 alkyl, —C(═O)C 1-6 alkyl, —OC(═O)C 1-6 alkyl, —C(═O)OC 1-6 alkyl, —S(O) 2 C 1-6 alkyl, —NR 13 R 14 , —C(═O)N(R 13 )(R 14 ), and —S(O) 2 NR 13 R 14 , wherein C 1-6 alkyl in all instances is optionally substituted with 1-5 halogens;
R 5 , R 13 and R 14 are each independently selected from the group consisting of H, C 1-5 alkyl, —C(═O)C 1-5 alkyl, and —S(O) 2 C 1-5 alkyl, wherein C 1-5 alkyl in all instances is optionally substituted with 1-5 halogens;
R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are each independently selected from the group consisting of H, halogen, —OH, and C 1-3 alkyl which is optionally substituted with 1-5 halogens;
R 12 is selected from the group consisting of H and C 1-7 alkyl which is optionally substituted with 1-5 halogens;
p is an integer from 0-3; and
q is 0 or 1.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar is selected from the group consisting of phenyl, naphthyl, and a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, and S,
wherein Ar is optionally substituted with one aromatic group selected from phenyl, phenoxy, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S and is optionally substituted with 1-3 substituents independently selected from halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-5 alkyl, —C 3-6 cycloalkyl, —OC 1-3 alkyl, —SC 1-3 alkyl, —C(═O)C 1-3 alkyl, —OC(═O)C 1-3 alkyl, —C(═O)OC 1-3 alkyl, —S(O) 2 C 1-3 alkyl, —NR 13 R 14 , —C(═O)N(R 13 )(R 14 ), —S(O) 2 NR 13 R 14 , and —OC 3-6 cycloalkyl, wherein (a) C 1-3 alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC 1-3 alkyl optionally substituted with 1-5 halogens, (b) C 1-5 alkyl is optionally substituted with 1-5 halogens, (c) —C 3-6 cycloalkyl in all instances is optionally substituted with 1-2 substituents independently selected from halogen and CH 3 , and (d) the aromatic substituent group selected from phenyl, phenoxy, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O and S is optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-5 alkyl, —OC 1-3 alkyl, —SC 1-3 alkyl, —C(═O)C 1-3 alkyl, —OC(═O)C 1-3 alkyl, —C(═O)OC 1-3 alkyl, —S(O) 2 C 1-3 alkyl, NR 13 R 14 , —C(═O)N(R 13 )(R 14 ), —S(O) 2 NR 13 R 14 , and —O(CH 2 )q(4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N), wherein C 1-3 alkyl in all instances is optionally substituted with 1-5 halogens and optionally 1 group selected from —OH and —OC 1-3 alkyl optionally substituted with 1-5 halogens, C 1-5 alkyl is optionally substituted with 1-5 halogens, and the 4-6 membered heterocycle having 1-2 heteroatoms independently selected from O, S and N is optionally substituted with 1-2 groups independently selected from halogen, CH 3 , and CF 3 .
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar is selected from the group consisting of phenyl, naphthyl, quinolyl, pyridyl, and thiazolyl, wherein Ar is optionally substituted with one aromatic group selected from phenyl, phenoxy, and oxadiazolyl, and is optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, —OC 1-2 alkyl, and —OC 3-6 cycloalkyl, wherein C 1-4 alkyl and —OC 1-2 alkyl are optionally substituted with 1-5 halogens, and the substituents phenyl, phenoxy, and oxadiazolyl are optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , —OH, —C(═O)OH, C 1-4 alkyl, —OC 1-4 alkyl, and —O(CH 2 )q(4-6 membered cyclic ether), wherein C1-4alkyl in all instances is optionally substituted with 1-5 halogens and is optionally substituted with 1 group selected from —OH and —OC 1-3 alkyl optionally substituted with 1-5 halogens, and the 4-6 membered cyclic ether is optionally substituted with 1-2 groups independently selected from halogen, CH 3 , and CF 3 .
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
Z is selected from the group consisting of —C(═O)OR 12 , —C(═O)NR 13 R 14 , and 5-tetrazolyl;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of H, F, Cl, C 1-3 alkyl, and CF 3 ;
R 4 is selected from the group consisting of halogen, —CN, —NO 2 , —OH, —C(═O)H, —C(═O)OH, C 1-4 alkyl, —OC 1-4 alkyl, —C(═O)C 1-4 alkyl, and —NR 13 R 14 , wherein C 1-4 alkyl in all instances is optionally substituted with 1-5 halogens;
R 5 is selected from the group consisting of H, C 1-3 alkyl, and —C(═O)C 1-3 alkyl, wherein C 1-3 alkyl and —C(═O)C 1-3 alkyl are optionally substituted with 1-5 F;
R 6 , R 8 , and R 10 are each independently selected from the group consisting of H, —OH, and CH 3 ;
R 7 , R 9 , and R 11 are each independently selected from the group consisting of H and CH 3 ;
R 13 and R 14 are each independently selected from the group consisting of H, C 1-5 alkyl, and —S(O) 2 C 1-5 alkyl;
p is 0 or 1; and
q is 0 or 1.
5. The compound of claim 3 , or a pharmaceutically acceptable salt thereof,
wherein X is selected from the group consisting of —O—, —S—, —S(O)—, —S(O) 2 —, —CHR 11 O—, —CH 2 NH—, —OCH 2 —, and —CH 2 CH 2 O—;
Y is selected from the group consisting of —S—, —S(O)—, —S(O) 2 —, —O—, —OCH 2 —, —C(═O)—, —CHR 6 —, —NR 5 —, and —CH 2 CH 2 —;
Z is selected from the group consisting of —C(═O)OR 12 , —C(═O)NR 13 R 14 , and 5-tetrazolyl;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of H, CH 3 , and CF 3 ;
R 4 is selected from the group consisting of halogen, CH 3 , and CF 3 ;
R 5 is selected from the group consisting of H and CH 3 ;
R 6 is selected from the group consisting of H and —OH;
R 11 is selected from H and CH 3 ;
R 12 is selected from the group consisting of H and C 1-5 alkyl which is optionally substituted with 1-5 halogens;
R 13 is selected from the group consisting of H, C 1-3 alkyl, and —S(O) 2 C 1-3 alkyl;
R 14 is H;
p is 0 or 1; and
q is 0 or 1.
6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein
Ar is selected from the group consisting of phenyl, naphthyl, pyridyl, and thiazolyl, wherein Ar is optionally substituted with one aromatic group selected from phenyl, phenoxy, and oxadiazolyl, and is optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, —OC 1-2 alkyl, and —OC 3-6 cycloalkyl, wherein C 1-4 alkyl and —OC 1-2 alkyl are optionally substituted with 1-5 halogens, and the substituents phenyl, phenoxy, and oxadiazolyl are optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , —OH, C 1-3 alkyl, —OC 1-3 alkyl, and —O(CH 2 )q(4-6 membered cyclic ether), wherein C 1-3 alkyl is optionally substituted with 1-3 halogens, and —OC 1-3 alkyl is optionally substituted with 1-3 halogens and is optionally substituted with 1 group selected from —OH and —OC 1-3 alkyl optionally substituted with 1-3 halogens, and the 4-6 membered cyclic ether is optionally substituted with 1-2 groups independently selected from halogen, CH 3 and CF 3 ;
X is selected from the group consisting of —O—, —CHR 11 O—, —CH 2 NH—, —OCH 2 —, and —CH 2 CH 2 )—;
Y is selected from the group consisting of —S—, —S(O) 2 —, —O—, —OCH 2 —, —C(═O)—, —CHR 6 —, and —CH 2 CH 2 —;
Z is selected from the group consisting of —C(═O)OR 12 , —C(═O)NR 13 R 14 , and 5-tetrazolyl;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of H and CH 3 ;
R 6 is selected from the group consisting of H and —OH;
R 11 is selected from H and CH 3 ;
R 12 is H;
R 13 is selected from the group consisting of H, C 1-3 alkyl, and —S(O) 2 C 1-3 alkyl;
R 14 is H;
p is 0; and
q is 0 or 1.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein p is 0; and Ar is substituted with 1-3 substituent groups.
8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein
Ar is selected from the group consisting of
(a) phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, —OC 1-2 alkyl, and —OC 3-6 cycloalkyl, wherein C 1-4 alkyl and —OC 1-2 alkyl are optionally substituted with 1-3 halogens, and wherein phenyl is optionally substituted with one group selected from (i) phenyl, which is optionally substituted with 1-3 substituents independently selected from halogen, —CN, —NO 2 , CH 3 , —OCH 3 , CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 CH 2 OC 1-2 alkyl, and —O(CH 2 )q(4-6 membered cyclic ether selected from oxetane and tetrahydropyran), wherein the 4-6 membered cyclic ether is optionally substituted with 1 group selected from halogen, CH 3 , and CF 3 ; (ii) phenoxy, which is optionally substituted with 1-3 groups independently selected from CH 3 , CF 3 , and halogen; and (iii) 1,2,4-oxadiazol-3-yl, which is optionally substituted with 1-2 CH 3 groups;
(b) naphthyl, which is optionally substituted with 1-2 groups independently selected from CH 3 , CF 3 , halogen, and —CN;
(c) pyridyl, which is optionally substituted with 1-2 groups independently selected from CH 3 , CF 3 , and halogen; and
(d) 1,3-thiazol-5-yl, which is optionally substituted with 1-2 substituents independently selected from phenyl, CH 3 , and halogen;
X is selected from the group consisting of —O—, —CH 2 O—, —CH(CH 3 )O—, —CH 2 CH 2 O—, —CH 2 NH—, and —OCH 2 —;
Y is selected from the group consisting of —S—, —S(O) 2 —, —O—, —OCH 2 —, —C(═O)—, —CH(OH)—, —CH 2 —, and —CH 2 CH 2 —;
Z is selected from the group consisting of —C(═O)OH, —C(═O)NR 13 R 14 , and 5-tetrazolyl;
R 1 , R 2 , and R 3 are each independently selected from the group consisting of H and CH 3 ;
R 13 is selected from the group consisting of H, C 1-3 alkyl, and —S(O) 2 C 1-3 alkyl;
R 14 is H;
p is 0; and
q is 0 or 1.
9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein
Ar is phenyl, wherein phenyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, CF 3 , —OCF 3 , —OCHF 2 , —OC 1-2 alkyl, and —O-cyclopropyl, and is optionally substituted with one group selected from (i) phenyl, which is optionally substituted with 1-3 substituents independently selected from halogen, —CN, —NO 2 , CH 3 , —OCH 3 , CF 3 , —OCF 3 , —OCH 2 CH 2 OC 1-2 alkyl, and —O(CH 2 )q(4-6 membered cyclic ether selected from oxetane and tetrahydropyran), wherein the 4-6 membered cyclic ether is optionally substituted with 1 group selected from CH 3 , and CF 3 ; (ii) phenoxy, which is optionally substituted with 1-3 groups independently selected from CH 3 , CF 3 , and halogen; and (iii) 1,2,4-oxadiazol-3-yl, which is optionally substituted with 1- 2 CH 3 groups;
X is selected from the group consisting of —O— and —CH 2 O—;
Y is O;
Z is selected from the group consisting of —C(═O)OH and —C(═O)NR 13 R 14 ;
R 13 is, selected from the group consisting of H, CH 3 , and —S(O) 2 CH 3 ; and
R 14 is H.
10. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds having the following structures:
11. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
12. A method of treating type 2 diabetes mellitus in a patient in need of treatment comprising the administration to the patient of a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising
(1) a compound of claim 1 or a pharmaceutically acceptable salt thereof;
(2) one or more compounds selected from the group consisting of:
(a) PPAR gamma agonists and partial agonists;
(b) biguanides;
(c) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
(d) dipeptidyl peptidase IV (DP-IV) inhibitors;
(e) insulin or an insulin mimetic;
(f) sulfonylureas;
(g) α-glucosidase inhibitors;
(h) agents which improve a patient's lipid profile, said agents being selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) bile acid sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists, (v) cholesterol absorption inhibitors, (vi) acyl CoA:cholesterol acyltransferase (ACAT) inhibitors, (vii) CETP inhibitors, and (viii) phenolic anti-oxidants;
(i) PPARα/γdual agonists,
(j) PPARδ agonists,
(k) antiobesity compounds,
(l) ileal bile acid transporter inhibitors;
(m) anti-inflammatory agents;
(n) glucagon receptor antagonists;
(o) GLP-1;
(p) GIP-1;
(q) GLP-1 analogs; and
(r) HSD-1 inhibitors; and
(3) a pharmaceutically acceptable carrier.